Skip to main content
Log in

A reduction in between subject variability is not mandatory for selecting a new covariate

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed between subject variance (BSV). The overall variability in a parameter within a population termed population parameter variance (PPV) consists of within subject variance (WSV) and BSV. Both these variances can further be split into random and predictable components. The predictable component of BSV (termed BSVP) is explained by covariates, individual characteristics e.g. weight. As BSVP increases, the remaining unpredictable (or random) between subject variability (BSVR) decreases since BSV = BSVP + BSVR, and BSV is a constant in any given data set. Since BSV and BSVR are estimated from the base and full covariate models, respectively, then BSVP = BSV−BSVR. The aim of this study was to explore the hypothesis, that a significant covariate may not always decrease BSVR. The specific aims were: (1) to explore circumstances where BSVR may not be reduced when adding a significantly correlated covariate and (2) to explore whether specific models for covariates may eliminate this anomaly when assessing BSVR. Simulations were performed using MATLAB (2011a) and estimation using NONMEM (ver 7.2) with FOCE and INTERACTION. A 1-compartment intravenous bolus PK model was used for simulation following a single unit dose (d = 1). The BSV of clearance [BSV(CL)] was described according to a log-normal distribution model with mean zero and variance \( \omega^{ 2} \). An additive random unexplained variability was assumed. Initially, we show through a simple simulation that BSVR can increase when a significantly correlated covariate is added to the model. We follow this with five simulation scenarios, A to E, that have various levels of correlation between the continuous covariate (Z) and CL ranging from 0 to 100 %. Each simulated scenario was replicated 100 times and estimated by a base model (i.e. without covariate addition) and six covariate models (M1–M6) which included non-nested (M1), nested (M2), and two types of interaction models for each of M1 and M2; non-nested interaction (M3, M5), nested interaction (M4, M6). Initially, through a motivating example we show that BSVR may not reduce even when there is 50 % correlation between the covariate Z and CL. It was found that with 0 % correlation M1, the non-nested covariate model (NNCM) resulted in negative BSVP (inflated BSVR) whereas M2, the nested covariate model (NCM), resulted in a calculated BSVP of zero. NNCM (M1) shows negative BSVP (BSVR > BSV) with correlation as high as 50 % and this model needs a minimum of 75 % correlation to show a positive BSVP. NCM (M2) shows positive but downwardly biased BSVP with 25, 50 and 75 % correlations. However, inclusion of a covariate–eta interaction term for both types of covariate models resulted in greater BSVP for 25, 50 and 75 % correlation scenarios compared to NNCM and NCM respectively. For 100 % correlation, it was found that covariate–eta interaction models show the same BSVP as the models without the interaction term, i.e. under perfect positive correlation all models perform similarly and correctly. It was found that a significantly correlated covariate may not reduce BSVR and in fact it may inflate the BSVR due to statistical misspecification of the covariate model. Incorporating statistical models that account for the covariate–eta interaction may be useful diagnostically in identifying the variability explained by covariates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Bonate PL (2005) Pharmacokinetic-pharmacodynamic modelling and simulation. Springer, New York

    Google Scholar 

  2. Duffull SB, Wright DF, Winter HR (2011) Interpreting population pharmacokinetic-pharmacodynamic analyses—a clinical viewpoint. Br J Clin Pharmacol 71:807–814

    Article  PubMed  CAS  Google Scholar 

  3. Green B, Duffull SB (2003) Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 56:96–103

    Article  PubMed  CAS  Google Scholar 

  4. Dartois C et al (2007) Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol 64:603–612

    Article  PubMed  CAS  Google Scholar 

  5. Matthews I, Kirkpatrick C, Holford N (2004) Quantitative justification for target concentration intervention–parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 58:8–19

    Article  PubMed  CAS  Google Scholar 

  6. Chan PL, Nutt JG, Holford NH (2005) Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson’s disease. J Pharmacokinet Pharmacodyn 32:307–331

    Article  PubMed  CAS  Google Scholar 

  7. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165:819–829

    Article  PubMed  Google Scholar 

  8. Holford NHG (2001) Concentration controlled therapy. International Congress Series 1220,135–144

  9. Lin L et al (2012) Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. Paediatr Anaesth 22:318–326

    Article  PubMed  Google Scholar 

  10. Ribbing J, Jonsson EN (2004) Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 31:109–134

    Article  PubMed  CAS  Google Scholar 

  11. Duffull S, Eccleston J, Kimko H and Denman N (2009) WinPOPT user guide. [http://www.winpopt.com/]. University of Otago, Dunedin

  12. Armitage P, Berry G (1994) Statistical methods in medical research. Blackwell Scientific Publications, Oxford

    Google Scholar 

Download references

Acknowledgments

We would like to acknowledge Mats Karlsson, Martin Bergstrand (Uppsala pharmacometrics group) & Stefanie Henning (University of Queensland) for their insightful comments on this project.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chakradhar V. Lagishetty.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 13 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lagishetty, C.V., Vajjah, P. & Duffull, S.B. A reduction in between subject variability is not mandatory for selecting a new covariate. J Pharmacokinet Pharmacodyn 39, 383–392 (2012). https://doi.org/10.1007/s10928-012-9256-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-012-9256-2

Keywords

Navigation